Elion Series B Funding Gains $81M for Antifungal Treatment

Elion Therapeutics, a biotech company, has raised $81 million in a Series B fundraising investment for SF001, an initial stages polyene antifungal treatment.

The proposed drug is being studied as a potential early antifungal treatment for aggressive aspergillosis and suspected invasive fungal diseases. FDA granted the medication accelerated approval and qualified infectious disease product (QIDP) designations in the past year. A multiple-ascending dosage investigation has been initiated after the medicine was assessed in a single-ascending dose trial conducted on individuals for the first time.

Aspergillus fumigatus is one of the four fungal infections that the World Health Organisation has designated as a “critical priority,” says Henry Skinner, CEO of AMR Action Fund.

Elion’s chief medical officer Kieren Marr stated: “Invasive fungal infections (IFI) have reached historic levels of concern, largely due to increased medical reliance on biologic immunosuppression, more people with severe pulmonary disease at risk of IFI, and increased exposures associated with environmental changes.”